NASDAQ: OABIOmniab Inc Stock
$1.79+0.02 (+1.13%)
Updated Apr 17, 2025
OABI Price
$1.79
Fair Value Price
N/A
Market Cap
$218.62M
52 Week Low
$1.70
52 Week High
$4.96
P/E
-2.93x
P/B
0.76x
P/S
13.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$26.39M
Earnings
-$62.03M
Gross Margin
100%
Operating Margin
-270.59%
Profit Margin
-235.1%
Debt to Equity
0.13
Operating Cash Flow
-$40M
Beta
0.51
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
OABI Overview
Avista Public Acquisition Corp. II is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar combinations with one or more businesses. The company is the second special purpose acquisition company sponsored by Avista Acquisition LP II. It targets healthcare companies. AHPA was incorporated in 2021 and is based in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OABI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OABI
Ranked#155 of 463
Ranked#155 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important OABI news, forecast changes, insider trades & much more!
OABI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OABI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OABI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OABI is good value based on its book value relative to its share price (0.76x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
OABI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OABI due diligence checks available for Premium users.
Valuation
OABI fair value
Fair Value of OABI stock based on Discounted Cash Flow (DCF)
Price
$1.79
Fair Value
-$3.77
Undervalued by
147.53%
OABI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OABI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.93x
Industry
-177.72x
Market
27.98x
OABI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
4.05x
OABI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OABI's financial health
Profit margin
Revenue
$10.8M
Net Income
-$13.1M
Profit Margin
-121%
OABI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OABI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$325.6M
Liabilities
$37.9M
Debt to equity
0.13
OABI's short-term assets ($68.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OABI's short-term assets ($68.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OABI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
$385.0k
Financing
$3.8M
OABI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OABI vs Biotech Stocks
Omniab Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.